Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)
Brief Summary: To investigate the superiority of a combination of irinotecan and cisplatin and the non-inferiority of S-1 compared to continuous infusion of 5-FU in advanced gastric cancer


Options:
A: Arm Label: Arm N - Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N-I, Level 1: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2b: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2c: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm N - Nivolumab, Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib
B: Arm Label: Physician choice chemotherapy+Best Supportive Care (BSC); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan, Drug: Paclitaxel, Other: Best Supportive Care (BSC) | Arm Label: Avelumab+BSC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avelumab, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Avelumab+BSC | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Avelumab+BSC, Physician choice chemotherapy+Best Supportive Care (BSC)
C: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: docetaxel, Drug: irinotecan | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): Chemotherapy

Answer: C